Clinical Trial Update: Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating immunogenicity and safety of a two-dose Menactra series in healthy Japanese adults. The study has completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcal Meningitis | Phase 4 | Status: COMPLETED | Results posted: 2017-11-06